Literature DB >> 8478264

Studies on the mode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyranoside and calcium.

T Ueki1, M Oka, Y Fukagawa, T Oki.   

Abstract

Sequence of reactions in the process of ternary complex formation of BMY-28864 with D-mannopyranoside and calcium was spectrophotometrically determined under more strict analytical conditions using metal-free preparations of sugars and the pradimicin derivative at a bandpass slit width of 1 nm. In the first phase of ternary complex formation, BMY-28864 stereospecifically recognized and bound to D-mannopyranoside in the absence of calcium, which was revealed by a visible absorption maximum shift of ca. 8 nm. Subsequently, the BMY-28864-D-mannopyranoside conjugate reacted with calcium to yield the ternary complex, which was detected by an additional visible absorption maximum shift of ca. 8 nm. When the three components were mixed at the same time, both phases simultaneously occurred to produce the ternary complex which was accompanied by a visible absorption maximum shift of 16 nm in total. Based on this two-phased reaction sequence, the mechanism of ternary complex formation of BMY-28864 with D-mannopyranoside and calcium was reexamined in details. Terminal D-mannopyranoside was confirmed to be essential as BMY-28864-specific sugar receptor by in vitro analysis and animal cell experiments. While calcium, strontium and cadmium behaved similar in the in vitro ternary complex formation, the yeast and animal cell experiments showed that only calcium played a dual role as a base in the ternary complex formation and as an effector in physiological disturbances leading to cell death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478264     DOI: 10.7164/antibiotics.46.465

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

Review 2.  Pradimicins: a novel class of broad-spectrum antifungal compounds.

Authors:  T J Walsh; N Giri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

3.  Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

Authors:  Jan Balzarini; Katrien O François; Kristel Van Laethem; Bart Hoorelbeke; Marleen Renders; Joeri Auwerx; Sandra Liekens; Toshikazu Oki; Yasuhiro Igarashi; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

Review 4.  Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.

Authors:  K O François; J Balzarini
Journal:  Med Res Rev       Date:  2010-06-23       Impact factor: 12.944

5.  Mannose-binding analysis and biological application of pradimicins.

Authors:  Yu Nakagawa; Yukishige Ito
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2022       Impact factor: 3.493

Review 6.  Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy.

Authors:  Jan Balzarini
Journal:  Nat Rev Microbiol       Date:  2007-08       Impact factor: 60.633

7.  The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120.

Authors:  Jan Balzarini
Journal:  FEBS Lett       Date:  2007-04-25       Impact factor: 4.124

Review 8.  Molecular architecture and therapeutic potential of lectin mimics.

Authors:  Yu Nakagawa; Ito Yukishige
Journal:  Adv Carbohydr Chem Biochem       Date:  2012       Impact factor: 12.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.